Description
Filstim (Filgrastim) Solution for Injections 1ml (30 ml, n IU) 0.3 mg – Syringe
Ingredients
Filstim contains the active ingredient filgrastim in a 0.3 mg/ml solution for injections.
Mechanism of Action
Filgrastim acts on hematopoietic cells to stimulate the production and maturation of neutrophils, enhancing the body’s ability to fight infections.
Pharmacological Properties
Clinical trials have shown that filgrastim can significantly reduce the duration and severity of neutropenia, leading to improved treatment outcomes in cancer patients.
Indications for Use
Filstim is commonly used to stimulate the production of white blood cells in patients undergoing chemotherapy or bone marrow transplantation.
Contraindications
Filstim is contraindicated in patients with a history of serious allergic reactions to filgrastim or any of the components in the formulation.
Side Effects
It is essential to monitor patients receiving Filstim for signs of spleen enlargement or other serious side effects.
Usage Instructions
Filstim should be administered by injection under the skin or into a vein as directed by a healthcare provider. Proper injection techniques should be followed to avoid complications.
Benefits Compared to Analogues
Compared to similar drugs, Filstim has demonstrated comparable efficacy with a favorable safety profile. Its convenient dosage form and proven effectiveness make it a preferred choice for healthcare providers managing neutropenia in cancer patients.
Suitable Patient Groups
Filstim is suitable for patients undergoing chemotherapy or bone marrow transplantation, including children and elderly individuals.
Storage and Shelf Life
Filstim should be stored according to the manufacturer’s instructions. It has a specific shelf life that should be adhered to for optimal efficacy.
Packaging Description
Filstim is available in syringe packaging for easy administration.
Clinical Evidence and Proven Effectiveness
Studies have shown that filgrastim is effective in reducing the incidence of febrile neutropenia in cancer patients undergoing chemotherapy. Research published in the Journal of Clinical Oncology demonstrated the efficacy of filgrastim in improving neutrophil counts and reducing the risk of infections.
